Holen Sie sich die Stockscreener-App
20.62
5.69%
1.11
Vorhandelsmarkt:
21.50
0.88
+4.27%
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Stempoint Capital LP - MarketBeat
Hsbc Holdings PLC Boosts Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG Research - MarketBeat
SNDX: BTIG Reiterates "Buy" Rating with Price Target of $56 | SN - GuruFocus
TD Cowen reiterates Buy rating on Syndax Pharmaceuticals stock By Investing.com - Investing.com Canada
Syndax Pharmaceuticals (SNDX): Valuation Check After Positive Revuforj Data at the 67th ASH Meeting - Yahoo Finance
Is Syndax Pharmaceuticals Fairly Priced After Recent Oncology Pipeline Momentum? - Yahoo Finance
Transcript : Syndax Pharmaceuticals, Inc. Presents at The 67th American Society of Hematology Annual Meeting, Dec-08-2025 07 - marketscreener.com
Syndax Pharmaceuticals Highlights Promising Efficacy and Safety Data for Revuforj® at the 67th ASH Annual Meeting - Quiver Quantitative
Syndax Highlights Leadership in Menin Inhibition at ASH - GlobeNewswire
Schroder Investment Management Group Buys 64,598 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer - AOL.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Tema Etfs LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Syndax Pharmaceuticals stock hits 52-week high at 20.25 USD By Investing.com - Investing.com Australia
Saturn V Capital Management LP Sells 540,729 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Stonepine Capital Management LLC Buys New Shares in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Capital Fund Management S.A. Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Why Syndax Pharmaceuticals Inc. (1T3) stock could rally strongly2025 Macro Impact & Weekly Watchlist for Consistent Profits - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsQuarterly Portfolio Report & Verified Momentum Watchlists - Newser
Is Syndax Pharmaceuticals Inc. (1T3) stock a buy during volatile marketsCPI Data & Safe Capital Growth Tips - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Is Syndax Pharmaceuticals Inc. (1T3) stock positioned for digital growth eraWeekly Gains Summary & Real-Time Volume Spike Alerts - Newser
Syndax Pharmaceuticals (SNDX) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Is Syndax Pharmaceuticals Inc a good long term investmentEarnings Growth Projections & Maximize Returns With Insights - earlytimes.in
What insider purchases suggest about Syndax Pharmaceuticals Inc. (1T3) stockMarket Movement Recap & High Accuracy Swing Entry Alerts - Newser
Can Syndax Pharmaceuticals Inc. (1T3) stock reach $200 price targetCEO Change & High Return Trade Opportunity Guides - Newser
CFO Goldan Gifts 1,224 Of Syndax Pharmaceuticals Inc [SNDX] - TradingView
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference - The Manila Times
Geode Capital Management LLC Has $19.20 Million Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Will Syndax Pharmaceuticals Inc. stock beat EPS estimates2025 Analyst Calls & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Syndax Pharmaceuticals, Inc. $SNDX is Aisling Capital Management LP's 3rd Largest Position - MarketBeat
Syndax: Early Commercial Momentum Points Toward Strong 2026 Growth - Seeking Alpha
Syndax Pharmaceuticals, Inc. $SNDX Stock Position Boosted by Franklin Resources Inc. - MarketBeat
Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating - MSN
10 Most Promising Stocks with Huge Upside Potential - Insider Monkey
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Rhenman & Partners Asset Management AB - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month HighShould You Buy? - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 10.9% Higher After Analyst Upgrade - MarketBeat
Syndax Pharmaceuticals Shows Rising Price Performance With Jump To 92 RS Rating - MSN
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $35.00 at Barclays - MarketBeat
Barclays Maintains Syndax Pharmaceuticals (SNDX) Overweight Recommendation - Nasdaq
SNDX Analyst Update: Barclays Raises Price Target to $35 | SNDX Stock News - GuruFocus
Syndax Pharmaceuticals stock hits 52-week high at 18.14 USD By Investing.com - Investing.com Canada
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 29% But Growth Is Lacking - 富途牛牛
Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) Shares Climb 29% But Its Business Is Yet to Catch Up - simplywall.st
Mizuho Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year HighHere's Why - MarketBeat
Is Syndax Pharmaceuticals Inc. stock poised for growthWeekly Trend Summary & Fast Entry High Yield Stock Tips - newser.com
How Syndax Pharmaceuticals Inc. (1T3) stock compares with tech leadersWeekly Trend Summary & Long Hold Capital Preservation Tips - newser.com
Syndax at Jefferies: Strategic Growth in Hematologic Therapies By Investing.com - Investing.com Canada
Is Syndax Pharmaceuticals Inc. stock attractive for ETFsJuly 2025 Macro Moves & Entry and Exit Point Strategies - newser.com
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):